Marksans Pharma Limited (BOM:524404)

Market Cap	83.37B
Revenue (ttm)	27.31B
Net Income (ttm)	3.52B
Shares Out	n/a
EPS (ttm)	7.76
PE Ratio	23.71
Forward PE	19.47
Dividend	0.80 (0.42%)
Ex-Dividend Date	Aug 1, 2025

Volume	14,851
Average Volume	78,630
Open	190.00
Previous Close	190.05
Day's Range	187.20 - 190.60
52-Week Range	162.05 - 358.50
Beta	n/a
RSI	44.84
Earnings Date	Nov 13, 2025

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, an...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 1,840
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524404

Financial Performance

In 2024, Marksans Pharma's revenue was 26.23 billion, an increase of 20.46% compared to the previous year's 21.77 billion. Earnings were 3.81 billion, an increase of 21.32%.